Mass production of uniform, disease-free seedlings through tissue culture and a specialized seedling production system
First written in FY2016. 12 of 14 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Using plant tissue-culture technology, a form of biotechnology, we have the technology to produce large quantities of high-quality, uniform, disease-free seedlings in a short period.」
The business continues to be based on mass production of uniform, disease-free seedlings through tissue culture, together with a seedling production division-of-labor system that supplies growers with the quantities they require. - FY2025-H1RestatedAnnual report
「During the interim cumulative consolidated period, the Group’s total research and development expenditure was ¥15.848 million. There were no material changes in the status of the Group’s research and development activities during the period.」
Research and development expenditure of ¥15.848 million was disclosed, while the filing stated that there were no material changes in the status of research and development activities. - FY2024-Q3RestatedAnnual report
「During the cumulative consolidated period through the third quarter, the Group’s total research and development expenditure was ¥25.253 million. There were no material changes in the status of the Group’s research and development activities during the period.」
Research and development expenditure of ¥25.253 million was disclosed, while the filing stated that there were no material changes in the status of research and development activities. - FY2024-Q2RestatedAnnual report
「The Group's research and development expenditure for the six-month period ended the second quarter was ¥15.739 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
Research and development expenditure of ¥15.739 million was disclosed, and the Company stated that there were no material changes in the status of its research and development activities. - FY2024-Q1RestatedAnnual report
「The Group's research and development expenditure for the three-month period ended the first quarter was ¥8.483 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
Research and development expenditure of ¥8.483 million was disclosed, and the Company stated that there were no material changes in the status of its research and development activities. - FY2023-Q3RestatedAnnual report
「The Group's research and development expenditure for the nine-month period ended the third quarter was ¥23.879 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
Research and development expenditure of ¥23.879 million was disclosed, while the Company stated that there were no material changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「The Group's research and development expenditure for the six-month period ended the second quarter was ¥16.279 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
Research and development expenditure of ¥16.279 million was disclosed, while the Company stated that there were no material changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「The Group's research and development expenditure for the three-month period ended the first quarter was ¥9.136 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
Research and development expenditure of ¥9.136 million was disclosed, and the status of the research and development activities was said to be unchanged in any material respect. - FY2022-Q2RestatedAnnual report
「The Group's research and development expenditure for the six-month period ended the second quarter was ¥14.291 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
Research and development expenditure of ¥14.291 million was disclosed, while the Company stated that there were no material changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「The Group's research and development expenditure for the three-month period ended the first quarter was ¥7.999 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
Research and development expenditure of ¥7.999 million was disclosed, while the Company stated that there were no material changes in the status of its research and development activities. - FY2021AdvancedAnnual report
「During the consolidated fiscal year, the Company made capital investments of ¥26.848 million. The principal investments were ¥19.343 million for a new strawberry seedling production facility established to enable the Company to produce in-house on a stable basis seedlings previously produced mainly by external contractors, and ¥4.100 million to upgrade the air-conditioning equipment in the seedling culture room.」
The Company newly installed production equipment to produce in-house on a stable basis the strawberry seedlings previously produced by external contractors, and also upgraded the air-conditioning equipment in the seedling culture room. - FY2019RestatedAnnual report
「Using plant tissue-culture technology, a form of biotechnology, we have the technology to produce large quantities of high-quality, uniform, disease-free seedlings in a short period.」
The mass production of uniform, disease-free seedlings through tissue culture and a division-of-labor system supplying the required quantities to growers continue to be described as the business foundation. - FY2018RestatedAnnual report
「Using plant tissue-culture technology, a form of biotechnology, we have the technology to produce large quantities of high-quality, uniform, disease-free seedlings in a short period.」
The mass production of uniform, disease-free seedlings through tissue culture and a division-of-labor system supplying the required quantities to growers continue to be described as the business foundation. - FY2016First statedAnnual report
「Using plant tissue-culture technology, a form of biotechnology, we have the technology to produce large quantities of high-quality, uniform, disease-free seedlings in a short period.」
A division-of-labor system has been established for our own varieties, under which growers purchase the required quantity when needed rather than propagating seedlings themselves.